Trials / Terminated
TerminatedNCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Celldex Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malignancies (recipients) will be enrolled.
Conditions
- For Donors
- Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
- For Recipients
- Acute Myelogenous Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelogenous Leukemia (CML)
- Non-Hodgkins Lymphoma (NHL)
- Hodgkins Disease (HD)
- Chronic Lymphocytic Leukemia (CLL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDX-301 | Related donors will receive CDX-301 for 5 days or 7 days. |
| DRUG | CDX-301 and plerixafor | Related donors will receive CDX-301 for 5 or 7 days plus plerixafor. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-03-01
- Completion
- 2016-04-13
- First posted
- 2014-07-25
- Last updated
- 2017-04-07
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02200380. Inclusion in this directory is not an endorsement.